Sự khác biệt của tế bào biểu mô và mô đệm trong ung thư biểu mô tế bào vảy vùng đầu và cổ về phản ứng hóa trị ngoại vi

Wright JL, Cobb JP, Gumport SL, Golomb FM, Safadi D (1957) Investigation of the relation between clinical and tissue culture response to chemotherapeutic agents of human cancer. N Engl J Med 257:1207–1211 DiPaolo JA, Dowd JE (1961) Evaluation of inhibition of human tumor tissue by cancer chemotherapeutic drugs with an in vitro test. J Natl Cancer Inst 27:807–815 Courtenay VD, Mills J (1978) An in vitro colony assay for human tumours grown in immune-suppressed mice and treated in vivo with cytotoxic agents. Br J Cancer 37:261–268 Freeman AE, Hoffman RM (1986) In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA 83:2694–2698 Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffmann RM (1987) In vivo-like drug responses of human tumors growing in three-dimensional, gel-supported, primary culture. Proc Natl Acad Sci USA 84:5029–5033 Vescio RA, Connors KM, Bordin GM, Robb JA, Youngkin T, Umbreit JN, Hoffmann RM (1990) The distinction of small cell and non-small cell lung cancer by growth in native-state histoculture. Cancer Res 50:6095–6099 Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Kase S, Kodaira S, Ishibiki K, Kitajima M (1992) High in vitro correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 51:489–498 Robbins KT, Varki NM, Storniolo AM, Hoffman H, Hoffman RM (1991) Drug response of head and neck tumors in native-state histoculture. Arch Otolaryngol Head Neck Surg 117:83–86 Von Hoff DD (1990) He’s not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst 82:96–101 Dollner R, Granzow C, Werner JA, Dietz A (2004) Is there a role for chemosensitivity tests in head and neck cancer? Onkologie 27:310–315 Weisenthal LM, Lippman ME (1985) Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep 69:615–632 Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, Hagen R, Pfreundner L, Schröder U, Eckel H, Hess M, Schröder M, Schneider P, Jens B, Zenner HP, Werner JA, Engenhardt-Cabillic R, Vanselow B, Plinkert P, Niewald M, Kuhnt T, Budach W, Flentje M (2009) Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol 266(8):1291–1300 Rajaraman R, Guernsey DL, Rajaraman MM, Rajaraman SR (2006) Stem cells, senescence, neosis and self-renewal in cancer. Cancer Cell Int 6:25. doi:10.1186/1475-2867-6-25 Rajamaran R, Rajaraman MM, Rajaraman SR, Guernsey DL (2005) Neosis: a paradigm of self-renewal in cancer. Cell Biol Int 29:1084–1097 Heuser M, Kopun M, Rittgen W, Granzow C (2005) Cytotoxicity determination without photochemical artifacts. Cancer Lett 223:57–66 Granzow C, Kopun M, Kröber T (1995) Riboflavin-mediated photosensitization of Vinca alkaloids distorts drug sensitivity assays. Cancer Res 55:4837–4843 Wichmann G, Horn I-S, Boehm A, Mozet C, Tschöp K, Dollner R, Dietz A (2009) Single biopsies from head and neck squamous cell carcinomas are representative regarding the entire tumor’s chemosensitivity to cisplatin and docetaxel. Onkologie 32(5):264–272 Dietz A, Tschöp K, Wichmann G, Granzow C (2008) Method and kit for the ex vivo evaluation of the response of a tumor to conditions to be tested. US-Provisional Ser. No. 61/044,082 Cabelguenne A, Blons H, Waziers De I, Carnot F, Houllier A-M, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P (2000) p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 18:1465–1473 Fouret P, Temam S, Charlotte F, Lacau-St-Guily J (2002) Tumor stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumor response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck. Br J Cancer 87:1390–1395 Hoffmann TK, Sonkoly E, Hauser U, Lierop A, Whiteside TL, Klussmann JP, Hafner D, Schuler P, Friebe-Hoffmann U, Scheckenbach K, Erjala K, Gréman R, Schipper J, Bier H, Balz V (2008) Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol 44(12):1100–1109 Andrews GA, Xi S, Pomerantz RG, Lin CJ, Gooding WE, Wentzel AL, Wu L, Sidransky D, Grandis JR (2004) Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck 26:870–877 American Joint Committee on Cancer: Comparison Guide: Cancer Staging Manual Fifth versus Sixth Edition. http://www.cancerstaging.org/products/ajccguide.pdf. Accessed 31 March 2009 Dollner R, Kopun M, Dietz A, Wiessler M, Granzow C (2002) Chemoreactivity profiling of HNSCC: equipotentiality of platinum compounds and glufosfamide, a novel alkylating agent. Proc Am Assn Cancer Res 43:926–931 Dollner R, Granzow C, Helmke BM, Ruess A, Schad A, Dietz A (2004) The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma. Anticancer Res 24:325–331 Desoize B, Berthiot G, Manot L, Coninx P, Dumont P (1996) Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration. Eur J Cancer A 32:1734–1738 Bissett D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N, Kaye SB, Kerr DJ (1993) Phase I and pharmakokinetic study of Taxotere (RP 56976) administered as a 24-h infusion. Cancer Res 53:523–527 Witz IP, Levy-Nissenbaum O (2006) The tumor microenvironment in the post-PAGET era. Cancer Lett 242:1–10 Freeman AE, Hoffman RM (1986) In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA 83:2694–2698 Dollner R, Granzow C, Neudert M, Dietz A (2006) Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations. Anticancer Res 26:1651–1655 Granzow C, Kopun M, Heuser M, Herth F, Becker HD (2004) Chemoresistance of human lung tumor stromal cells. Am Assn Cancer Res 95th Annual Meeting Proc Suppl. abstract LB-82 Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A, Hyodo I, Ogawa T, Furukawa T (2007) Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 43:749–756 Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J (2002) Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24:437–442 Mukaida H, Hirabayashi N, Hirai T, Iwata T, Saeki S, Toge T (1991) Significance of freshly cultured fibroblasts from different tissues in promoting cancer cell growth. Int J Cancer 48:423–427 Zhang W, Matrisian LM, Holmbeck K, Vick CC, Rosenthal EL (2006) Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 6:52 Rosenthal EL, McCrory A, Talbert M, Carroll W, Magnuson JS, Peters GE (2004) Expression of proteolytic enzymes in head and neck cancer-associated fibroblasts. Arch Otolaryng Head Nack Surg 130:943–947 Song Z, Powell WC, Kasahara N, van Bokhoven A, Miller GJ, Roy-Burman P (2000) The effect of fibroblast growth factor 8, isoform b, on the biology of prostata carcinoma cells and their interaction with stromal cells. Cancer Res 60:6730–6736